No signs of mast cell involvement in long‐COVID: A case–control study
Scandinavian Journal of Immunology · 2024
DOI: 10.1111/sji.13407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2024. Verfasst von Ole Bernt Lenning und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Stavanger University Hospital, Stavanger, Norway. Hauptthemen laut MEDLINE: Mast Cells, COVID-19, Tryptases, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EkstraStiftelsen Helse og Rehabilitering (Stiftelsen Dam), Norwegian Brain Council, Stiftelsen Dam.
Abstract (Originalsprache)
Long‐COVID caused by SARS‐CoV‐2 infection has significant and increasing effects on human health worldwide. Although a unifying molecular or biological explanation is lacking, several pathophysiological mechanisms have been proposed. Involvement of mast cells—evolutionary old “multipurpose” innate immune cells—was reported recently in studies of acute infection and post‐acute‐COVID‐19 syndrome. Mast cell activity has been suggested in long‐COVID. In this case–control study, we compared data from 24 individuals with long‐COVID (according to the NICE criteria) and 24 age‐ and sex‐matched healthy individuals with a history of SARS‐CoV‐2 infection without developing sequelae. Serum levels of the proteases beta‐tryptase (TPSB2) and carboxypeptidase (CPA3), which are mast cell specific, were measured using immunoassays. The values were compared between the two groups and correlated to measures of physical exertional intolerance. TPSB2 and CPA3 levels were median (range) 26.9 (2.0–1000) and 5.8 (1.5–14.0) ng/mL, respectively, in the long‐COVID group. The corresponding values in the control group were 10.9 (2.0–1000) ( p = 0.93) and 5.3 (3.5–12.9) ng/mL ( p = 0.82). No significant correlations between TPSB2 or CPA3 levels and scores on the ten physical subscales of SF‐36, 3.1–3.10 were revealed. We found no significant differences in the levels of mast cell activation markers TPSB2 and CPA3 between the long‐COVID and control groups and no correlations with proxy markers of exercise intolerance. Mast cell activation does not appear to be part of long‐term pathogenesis of long‐COVID, at least in the majority of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Department, Stavanger University Hospital, Stavanger, Norway.
- Department of Medical Biochemistry, Stavanger University Hospital, Stavanger, Norway.
- Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.
- Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
ORCID-Profile: Ole Bernt Lenning, Geir Sverre Braut, Roald Omdal
Förderung
- EkstraStiftelsen Helse og Rehabilitering (Stiftelsen Dam)
- Norwegian Brain Council
- Stiftelsen Dam
Zitieren
APA
Lenning, O. B., Jonsson, G., Grimstad, T., Janssen, E. A. M., Braut, G. S., Berven, F., & Omdal, R. (2024). No signs of mast cell involvement in long‐COVID: A case–control study. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13407
Vancouver
Lenning OB, Jonsson G, Grimstad T, Janssen EAM, Braut GS, Berven F, et al. No signs of mast cell involvement in long‐COVID: A case–control study. Scandinavian Journal of Immunology. 2024. doi:10.1111/sji.13407
BibTeX
@article{Lenning2024,
author = {Lenning, Ole Bernt and Jonsson, Grete and Grimstad, Tore and Janssen, Emiel A M and Braut, Geir Sverre and Berven, Frode and Omdal, Roald},
title = {No signs of mast cell involvement in long‐COVID: A case–control study},
journal = {Scandinavian Journal of Immunology},
year = {2024},
doi = {10.1111/sji.13407}
}
EUVIMED